Rights and permissions
About this article
Cite this article
Rivastigmine for AD: clinical and economic benefits. Pharmacoecon. Outcomes News 268, 10 (2000). https://doi.org/10.1007/BF03267230
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03267230